Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Delavirdine Mesylate

FDA-approved product (tablet, oral), marketed as Rescriptor.

Registered studies
27
Lab records
0
Pathogens at ≥40%
2 of 4

Chemical structure

Chemical structure of Delavirdine Mesylate
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Viral disease

Indications ChEMBL records as approved, from FDA and DailyMed labels.

WHO therapeutic group
Non-nucleoside reverse transcriptase inhibitors
Anti-infective classification
Classified as another kind of anti-infective (for example an antifungal, antiviral or antiparasitic medicine).WHO ATC J05AG02

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against MRSA and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA51.7% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli38.8% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae33.5% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis58.9% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

27registered studies name this medicine, for any condition. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Delavirdine Mesylate in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-7.3 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-6.8 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-8.9 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-7.9 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Delavirdine Mesylate with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Study to Compare Bictegravir/Lenacapavir Versus Current Therapy in People With HIV-1 Who Are Successfully Treated With a Complicated Regimen

    NCT05502341 · start 2022-08-16

    Registered record
    Registry ID
    NCT05502341
    Conditions
    HIV-1-infection
    Interventions
    Bictegravir; Lenacapavir; BIC/LEN FDC; Stable Baseline Regimen
    Study type
    INTERVENTIONAL
    Phase
    Phase 2 / Phase 3
    Registry status
    Active not recruiting
    Start
    2022-08-16
    Completion
    2028-07
    Enrolment
    689

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV-1-infection
    InterventionBictegravir; Lenacapavir; BIC/LEN FDC; Stable Baseline Regimen
    PhasePhase 2 / Phase 3
    Registry statusActive not recruiting

  • Study to Evaluate Switching From a Regimen of Two Nucleos(t)Ide Reverse Transcriptase Inhibitors (NRTI) Plus a Third Agent to a Fixed Dose Combination (FDC) of Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF), in Virologically-Suppressed, HIV-1 Infected African American Participants

    NCT03631732 · start 2018-08-28

    Registered record
    Registry ID
    NCT03631732
    Conditions
    HIV-1 Infection
    Interventions
    B/F/TAF; NRTIs; Third Agent
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2018-08-28
    Completion
    2020-08-19
    Enrolment
    496

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV-1 Infection
    InterventionB/F/TAF; NRTIs; Third Agent
    PhasePhase 3
    Registry statusCompleted

  • Study of Cobicistat-Boosted Atazanavir (ATV/co), Cobicistat-Boosted Darunavir (DRV/co) and Emtricitabine/Tenofovir Alafenamide (F/TAF) in Children With HIV

    NCT02016924 · start 2014-01-16

    Registered record
    Registry ID
    NCT02016924
    Conditions
    Acquired Immune Deficiency Syndrome (AIDS); HIV Infections
    Interventions
    ATV; DRV; Cobicistat; BR; F/TAF; LPV/r; Third Unboosted Drug; Cobicistat TOS; F/TAF TOS
    Study type
    INTERVENTIONAL
    Phase
    Phase 2 / Phase 3
    Registry status
    Active not recruiting
    Start
    2014-01-16
    Completion
    2027-03
    Enrolment
    133

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAcquired Immune Deficiency Syndrome (AIDS); HIV Infections
    InterventionATV; DRV; Cobicistat; BR +5 more
    PhasePhase 2 / Phase 3
    Registry statusActive not recruiting

  • Quality of Life of HIV-infected Participants Switched to Raltegravir Versus Other Antiretroviral Regimens (MK-0518-266)

    NCT01814722 · start 2012-11-09

    Registered record
    Registry ID
    NCT01814722
    Conditions
    Human Immunodeficiency Virus
    Interventions
    Not recorded
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Terminated
    Start
    2012-11-09
    Completion
    2013-10-31
    Enrolment
    63

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHuman Immunodeficiency Virus
    InterventionNot recorded
    PhaseNot recorded
    Registry statusTerminated

  • CCR5 Inhibitor Treatment Intensification on CD4+ T-cell Recovery

    NCT00925756 · start 2008-10-20

    Registered record
    Registry ID
    NCT00925756
    Conditions
    HIV Infections
    Interventions
    Maraviroc
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2008-10-20
    Completion
    2014-04-11
    Enrolment
    32

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV Infections
    InterventionMaraviroc
    PhasePhase 4
    Registry statusCompleted

  • Clinical Trial of CNS-targeted HAART (CIT2)

    NCT00624195 · start 2007-03

    Registered record
    Registry ID
    NCT00624195
    Conditions
    HIV Infections
    Interventions
    FDA Approved Antiretroviral Therapy (see list below)
    Study type
    INTERVENTIONAL
    Phase
    Phase 2 / Phase 3
    Registry status
    Completed
    Start
    2007-03
    Completion
    2012-06
    Enrolment
    59

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV Infections
    InterventionFDA Approved Antiretroviral Therapy (see list below)
    PhasePhase 2 / Phase 3
    Registry statusCompleted

  • Safety of EVG+RTV Administered With Other Antiretroviral Agents for the Treatment of HIV-1 Infection

    NCT00445146 · start 2007-02

    Registered record
    Registry ID
    NCT00445146
    Conditions
    HIV Infections
    Interventions
    EVG; RTV; ARV regimen
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2007-02
    Completion
    2015-03
    Enrolment
    192

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV Infections
    InterventionEVG; RTV; ARV regimen
    PhasePhase 2
    Registry statusCompleted

  • Safety And Efficacy Of Rescriptor In Patients For Human Immunodeficiency Virus (HIV) Patients

    NCT00823966 · start 2003-12

    Registered record
    Registry ID
    NCT00823966
    Conditions
    HIV-1 Infection
    Interventions
    Rescriptor
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2003-12
    Completion
    2009-03
    Enrolment
    3

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV-1 Infection
    InterventionRescriptor
    PhaseNot recorded
    Registry statusCompleted

  • Safety and Effectiveness of 3 Anti-HIV Treatments in Patients Who Have Failed Previous Treatments Containing Nelfinavir

    NCT00006326 · start 2000-08

    Registered record
    Registry ID
    NCT00006326
    Conditions
    HIV Infections
    Interventions
    Indinavir sulfate; Ritonavir; Delavirdine mesylate
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Terminated
    Start
    2000-08
    Completion
    Not recorded
    Enrolment
    60

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV Infections
    InterventionIndinavir sulfate; Ritonavir; Delavirdine mesylate
    PhaseNot applicable
    Registry statusTerminated

  • Tipranavir Dose-response Study Using a Prototype Self-emulsifying Drug Delivery System (SEDDS) Formulation in Treatment-naive HIV-1 Infected Patients Report on the Post-study Option, a Treatment of Triple Therapy With Delavirdine, ZDV and 3TC Without Tipranavir

    NCT02249130 · start 1999-03

    Registered record
    Registry ID
    NCT02249130
    Conditions
    HIV Infections
    Interventions
    Tipranavir (TPV); Ritonavir (RTV); Delavirdine (DLV); Zidovudine (ZDV); Lamivudine (3TC); Stavudine (d4T)
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    1999-03
    Completion
    Not recorded
    Enrolment
    18

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV Infections
    InterventionTipranavir (TPV); Ritonavir (RTV); Delavirdine (DLV); Zidovudine (ZDV) +2 more
    PhasePhase 2
    Registry statusCompleted

  • A Phase II Double-Blind Study of Delavirdine Mesylate ( U-90152 ) in Combination With Zidovudine ( AZT ) and/or Didanosine ( ddI ) Versus AZT and ddI Combination Therapy

    NCT00000803

    Registered record
    Registry ID
    NCT00000803
    Conditions
    HIV Infections
    Interventions
    Delavirdine mesylate; Zidovudine; Didanosine
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    Not recorded
    Completion
    1997-03
    Enrolment
    471

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV Infections
    InterventionDelavirdine mesylate; Zidovudine; Didanosine
    PhasePhase 2
    Registry statusCompleted

  • Randomized, Phase I/II, Dose-Ranging, Open-Label Trial of the Anti-HIV Activity of Delavirdine Mesylate (DLV; U-90,152S)

    NCT00000810

    Registered record
    Registry ID
    NCT00000810
    Conditions
    HIV Infections
    Interventions
    Delavirdine mesylate; Zidovudine; Didanosine
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    Not recorded
    Completion
    1996-01
    Enrolment
    120

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV Infections
    InterventionDelavirdine mesylate; Zidovudine; Didanosine
    PhasePhase 1
    Registry statusCompleted

  • Virologic and Immunologic Activity of Continued Lamivudine (3TC) vs Delavirdine (DLV) in Combination With Indinavir (IDV) and Zidovudine (ZDV) or Stavudine (d4T) in 3TC-Experienced Subjects

    NCT00000882

    Registered record
    Registry ID
    NCT00000882
    Conditions
    HIV Infections
    Interventions
    Indinavir sulfate; Delavirdine mesylate; Lamivudine; Stavudine; Zidovudine
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    Not recorded
    Completion
    Not recorded
    Enrolment
    300

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV Infections
    InterventionIndinavir sulfate; Delavirdine mesylate; Lamivudine; Stavudine +1 more
    PhasePhase 2
    Registry statusCompleted

  • Immunologic and Virologic Consequences of Long-Term Highly Active Antiretroviral Therapy (HAART) in Subjects With Moderately Advanced HIV-1 Disease: A Follow-Up Study to ACTG 315

    NCT00000891

    Registered record
    Registry ID
    NCT00000891
    Conditions
    HIV Infections
    Interventions
    Ritonavir; Saquinavir; Delavirdine mesylate; Lamivudine; Stavudine; Zidovudine; Didanosine
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    Not recorded
    Completion
    2004-05
    Enrolment
    34

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV Infections
    InterventionRitonavir; Saquinavir; Delavirdine mesylate; Lamivudine +3 more
    PhasePhase 2
    Registry statusCompleted

  • A Study of Several Anti-HIV Drug Combinations in HIV-Infected Patients Who Have Used Indinavir

    NCT00000892

    Registered record
    Registry ID
    NCT00000892
    Conditions
    HIV Infections
    Interventions
    Ritonavir; Nelfinavir mesylate; Levocarnitine; Adefovir dipivoxil; Saquinavir; Delavirdine mesylate
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    Not recorded
    Completion
    1999-08
    Enrolment
    300

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV Infections
    InterventionRitonavir; Nelfinavir mesylate; Levocarnitine; Adefovir dipivoxil +2 more
    PhaseNot applicable
    Registry statusCompleted